The combination of KRAS G12C inhibitors (AMG510 or MRTX849) alongside a clinical‐stage small molecule FAK inhibitor IN10018 produced encouraging anti‐cancer effects against multiple cancer cell lines, CDX, and PDX models of KRAS G12C mutant cancers. This evidence concerns the gene PTK2 and cancer.